How the Civica Insulin Announcement Could Be Disruptive to the PBM Kickback Scheme

Yours truly has written an article. I have given some more serious thought to theCivica insulin announcement made on March 3, 2022 (my article has a link to the original press release) and I think it could be very disruptive to what I have dubbed the " PBM Kickback Scheme " . You can read my assessment below, or athttps://www.slideshare.net/ScottStrumello/civica-insulin-assessment.Ironically, this month ' sNew England Journal of Medicine also has a very interesting (and similar) analysis of the exact same topic (the Civica insulin announcement) in its " Perspective " section in an article entitled " A Radical Treatment for Insulin Pricing " (the link to the article can be found athttps://www.nejm.org/doi/full/10.1056/NEJMp2203001, although I ' m not sure you can buy per-article access to NEJM as unless you subscribe to NEJM, which is different from other journals).I opted to to self-publish my own article in Scribd because there were points which others have chosen to gloss over which I believe the diabetes world should understand. Those elements happen to be core business strategies. Still, my underlying assessment is essentially the same as the NEJM article, and I ' m generally in agreement with Harvard ' s Leemore Dafny: the Civica insulin effort stands to be disruptive. She generalizes it as being disruptive to pharmacy supply chain entities, whereas I believe it will be most disruptive to the PBM kickback scheme (hence my own article title).In her article, Harvard '...
Source: Scott's Web Log - Category: Endocrinology Tags: 2022 Biocon Biosimilar biosimilars Civica Civica Rx CivicaRx insulin Semglee Viatris Source Type: blogs